We need sfvictim back. I'm surprised at the delay-- the one thing though that occurred to me is that DEPO has meanwhile applied for an extension for the Nucynta patents and the judge may want to see that ruling happen first.
Cebranobopanol, initial Purdue deci$ion & looming patent extension all post-bid. Starboard characterizing that bid as "shareholder unfriendly" suggests a new flag going up with DEPO looking that much better.
Interesting that there are now two binary events looming--cebranopadol and potential Purdue boost to patent extension--neither of which was on the "horizon" when HZNP made its bid, From here however a successful outcome of at least one of the two looks essential to DEPO prospects.